Synereca Pharmaceuticals

Synereca Pharmaceuticals is a biotechnology startup that focuses on the development of orally active drugs to enhance the efficacy of existing antibiotics. Founded in 2009 and based in Chapel Hill, North Carolina, the company's product line includes prototypic RecA inhibitors, targeting a wide range of pathogenic bacteria such as E. coli associated with lung, urinary tract, and skin infections, as well as weaponizable gram-positive and gram-negative pathogens. The company received a $600.00KVenture Round investment on 04 August 2015, with i2E, Accele Venture Partners, and Oklahoma Seed Capital Fund being the major investors. Synereca Pharmaceuticals aims to address the critical need for new approaches to combat antibiotic resistance and enhance the effectiveness of antibiotics in treating various infections.